Koers ASLAN Pharmaceuticals Limited Taipei Exchange
Aandelen
6497
KYG054241099
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | - | Omzet 2025 * | - | Marktkapitalisatie | 339 mln. 10,41 mln. 9,75 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -2,14 mld. -65,49 mln. -61,3 mln. | Nettowinst (verlies) 2025 * | -1,82 mld. -55,8 mln. -52,23 mln. | EV/omzet 2024 * | - |
Nettoliquiditeiten 2024 * | - 0 0 | Nettoliquiditeiten 2025 * | - 0 0 | EV/omzet 2025 * | - |
K/w-verhouding 2024 * |
-0,13
x | K/w-verhouding 2025 * |
-0,19
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 99% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Founder | 51 | 01-01-10 | |
Director of Finance/CFO | 45 | 01-11-10 | |
Chief Tech/Sci/R&D Officer | - | 15-03-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Hoffman
BRD | Director/Board Member | 58 | 30-10-18 |
Chairman | 64 | 01-04-16 | |
Founder | 51 | 01-01-10 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,75% | 102 mld. | |
+2,26% | 96,09 mld. | |
+2,13% | 22,28 mld. | |
-16,87% | 21,4 mld. | |
-8,79% | 18,14 mld. | |
-39,98% | 17,02 mld. | |
-14,17% | 16,09 mld. | |
+4,99% | 13,83 mld. | |
+33,09% | 11,97 mld. |